IS8339A - Anti-NOGO receptor antagonists - Google Patents

Anti-NOGO receptor antagonists

Info

Publication number
IS8339A
IS8339A IS8339A IS8339A IS8339A IS 8339 A IS8339 A IS 8339A IS 8339 A IS8339 A IS 8339A IS 8339 A IS8339 A IS 8339A IS 8339 A IS8339 A IS 8339A
Authority
IS
Iceland
Prior art keywords
nogo receptor
nogo
receptor antagonists
antigen
disclosed
Prior art date
Application number
IS8339A
Other languages
Icelandic (is)
Inventor
H. S. Lee Daniel
R. Pepinsky Blake
Li Weiwei
A. Rabacchi Sylvia
K. Relton Jane
S. Worley Dane
M. Strittmatter Stephen
W. Y. Sah Dinah
Original Assignee
Biogen Idec Ma Inc.
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/025004 external-priority patent/WO2004014311A2/en
Application filed by Biogen Idec Ma Inc., Yale University filed Critical Biogen Idec Ma Inc.
Publication of IS8339A publication Critical patent/IS8339A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)

Abstract

Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.
IS8339A 2003-08-07 2006-03-07 Anti-NOGO receptor antagonists IS8339A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2003/025004 WO2004014311A2 (en) 2002-08-10 2003-08-07 Nogo receptor antagonists
PCT/US2004/002702 WO2005016955A2 (en) 2003-08-07 2004-01-30 Nogo receptor antagonists

Publications (1)

Publication Number Publication Date
IS8339A true IS8339A (en) 2006-03-07

Family

ID=34192565

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8339A IS8339A (en) 2003-08-07 2006-03-07 Anti-NOGO receptor antagonists

Country Status (11)

Country Link
EP (1) EP1660517A4 (en)
JP (1) JP2007501612A (en)
CN (1) CN1926147A (en)
AU (1) AU2004264405A1 (en)
BR (1) BRPI0413426A (en)
CA (1) CA2535007A1 (en)
IS (1) IS8339A (en)
MX (1) MXPA06001444A (en)
NO (1) NO20061081L (en)
PL (1) PL380274A1 (en)
WO (1) WO2005016955A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
CA2495121A1 (en) 2002-08-10 2004-02-19 Yale University Nogo receptor antagonists
ES2215469B1 (en) 2002-09-30 2005-12-16 Bsh Electrodomesticos España, S.A. AIR CONDITIONER.
ES2215470B1 (en) 2002-09-30 2005-12-16 Bsh Electrodomesticos España, S.A. AIR CONDITIONER.
PL2248899T3 (en) 2003-03-19 2015-10-30 Biogen Ma Inc NOGO receptor binding protein
KR101239542B1 (en) 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 Treatment of conditions involving demyelination
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
WO2006124627A2 (en) * 2005-05-12 2006-11-23 Biogen Idec Ma Inc. Methods of treating conditions involving neuronal degeneration
WO2007008732A2 (en) 2005-07-07 2007-01-18 Yale University Compositions and methods for suppressing axonal growth inhibition
CA2902070A1 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CN101277974A (en) 2005-09-30 2008-10-01 阿伯特有限及两合公司 Binding domains of proteins of the Repulsive Guide Molecule (RGM) protein family, functional fragments thereof and their uses
CA2640423C (en) 2006-01-27 2016-03-15 Biogen Idec Ma Inc. Nogo receptor antagonists
WO2008013782A2 (en) 2006-07-24 2008-01-31 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists
EP2081562B1 (en) 2006-09-20 2016-02-24 The Board of Regents of The University of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
JP5653622B2 (en) * 2006-11-21 2015-01-14 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Neutralizing monoclonal antibody against Nogo-66 receptor (NGR) and use thereof
WO2009094459A1 (en) 2008-01-22 2009-07-30 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP2011527572A (en) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Composition comprising a LINGO antibody or fragment
KR20120118002A (en) 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
MX381731B (en) 2012-05-14 2025-03-13 Biogen Ma Inc Leucine-rich repeat-containing immunoglobulin domain (LINGO-2) receptor-interacting protein antagonists for the treatment of conditions involving motor neurons.
JP2018504400A (en) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． LINGO-1 antagonist and use for treatment of demyelinating disorders
CN110488007A (en) * 2019-09-26 2019-11-22 天津华科泰生物技术有限公司 A kind of immunochromatographydetection detection card and preparation method thereof of quick detection glial fibrillary acidic albumen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4682999A (en) * 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
US20050221420A1 (en) * 2001-10-22 2005-10-06 Carmen Barske Nogo receptor homologues and their use

Also Published As

Publication number Publication date
CA2535007A1 (en) 2005-02-24
EP1660517A4 (en) 2006-10-04
MXPA06001444A (en) 2006-05-15
NO20061081L (en) 2006-04-18
WO2005016955A3 (en) 2006-07-20
PL380274A1 (en) 2007-01-22
AU2004264405A1 (en) 2005-02-24
JP2007501612A (en) 2007-02-01
EP1660517A2 (en) 2006-05-31
WO2005016955A2 (en) 2005-02-24
BRPI0413426A (en) 2006-10-17
CN1926147A (en) 2007-03-07

Similar Documents

Publication Publication Date Title
DK1534736T3 (en) Nogo receptor antagonists
PL380274A1 (en) Nogo receptor antagonists
WO2007089601A3 (en) Nogo receptor antagonists
CY1111097T1 (en) NOGO RECEPTOR'S COMMITMENT PROTEIN
DK1709081T3 (en) Fusion polypeptides that can activate receptors
ATE509032T1 (en) CHIMERIZED GM-CSF ANTIBODIES
CY1107339T1 (en) MU-1, MEMBER OF THE FAMILY CYTOTINE RECEPTORS
WO2002068646A3 (en) Mammalian cytokines; receptors; related reagents and methods
EP1433792A3 (en) Human receptor proteins, related reagents and methods
EA200600376A1 (en) ANTAGONISTS OF NOGO RECEPTOR
EP1212340A4 (en) 29 PROTEINS ASSOCIATED WITH HUMAN CANCER
WO2003104263A3 (en) CYTOKINES AND CYTOKINE RECEPTORS WITH REDUCED IMMUNOGENECITY
WO2005065711A3 (en) Mammalian receptor proteins; related reagents and methods